Humanwell Healthcare (600079) Q3 2025 earnings summary

Executive summary

• Net profit attributable to shareholders rose 11.56% year-over-year in Q3 2025, with a 6.22% increase for the first nine months of 2025.

• Operating cash flow for the first nine months increased 10.40% year-over-year.

• Basic and diluted EPS for the first nine months reached ¥1.03, up from ¥0.98 and ¥0.97, respectively, in the prior year.

Financial highlights

• Q3 2025 revenue was ¥5.82 billion, down 7.36% year-over-year; nine-month revenue was ¥17.88 billion, down 6.58%.

• Q3 2025 net profit attributable to shareholders was ¥533.91 million, up 11.56% year-over-year.

• Net cash from operating activities for the first nine months was ¥1.65 billion, up 10.40% year-over-year.

• Gross margin and operating profit improved, with total profit for the first nine months at ¥2.63 billion, up 1.65% year-over-year.

Outlook and guidance

• A new three-year financial services agreement was signed with a group finance company, providing up to ¥2 billion in deposits and ¥5 billion in credit lines.